Gene therapies will only become a widespread tool in the clinical treatment of human diseases with the advent of gene transfer vectors that integrate genetic information stably, safely, effectively, and economically. Two decades after the discovery of the Sleeping Beauty (SB) transposon, it has been transformed into a vector system that is fulfilling these requirements. SB may well overcome some of the limitations associated with viral gene transfer vectors and transient non-viral gene delivery approaches that are being used in the majority of ongoing clinical trials. The SB system has achieved a high level of stable gene transfer and sustained transgene expression in multiple primary human somatic cell types, representing crucial steps that may permit its clinical use in the near future. Here we review the most important aspects of SB as a tool for gene therapy, including aspects of its vectorization and genomic integration. As an illustration we highlight clinical development of the SB system towards gene therapy of age-related macular degeneration and cancer immunotherapy.
Non-viral gene transfer using the Sleeping Beauty transposon
DNA transposons are genetic elements with the ability to change their positions within the genome. They mainly achieve this through a cut-and-paste mechanism. Natural transposons are mobile ("jumping") units of DNA encoding a gene for a transposase enzyme flanked by terminal inverted repeats (TIRs) that represent the sites where the transposase binds (Fig. 1A) . A crucial point in turning transposons into vectors is the possibility of separating these two functions (the TIRs and the transposase) to establish a two-component system: one component supplying the transposase and the other component carrying a DNA sequence of interest between the TIRs (Fig. 1B) . The transposase enzyme mediates the excision of the element from its donor plasmid, then reintegrates the transposon construct into a chromosomal locus (Fig. 1C) . The result is an easily controllable DNA delivery vehicle that has a vast potential for diverse applications in genetic engineering, including gene therapies.
Although over the course of evolution transposons became dormant in vertebrates, it was possible to reconstruct an active sequence from ancient inactive transposon sequences isolated from fish genomes. This transposon was named Sleeping Beauty (SB) after the Grimm brothers' famous fairy tale 1 . SB was the first transposon ever shown to be capable of efficient transposition in vertebrate cells, and it opened entirely new avenues for genetic engineering. A vision developed of using SB for gene therapies (reviewed in [2] [3] [4] [5] [6] [7] [8] [9] [10] ). A transposon-based gene delivery system would have the advantage of combining the favorable features of viral vectors with those of naked DNA molecules. First, permanent insertion of transgene constructs into the genome by the transpositional mechanism (in the case of SB this occurs at genomic TA dinucleotides 1 ) leads to sustained and efficient transgene expression in preclinical animal models 6 . Second, in contrast to viral vectors, transposon vectors can be maintained and propagated as plasmid DNA, which makes them simple and inexpensive to manufacture, another important consideration for implementations and a scale-up into real clinical practice. SB has further advantages as a gene-transfer system: its immunogenicity in vivo is much lower than that of viral vectors 11 ; it can deliver larger genetic cargoes 12 , and poses far fewer safety issues 9, [13] [14] [15] . Another transposon that has become a widely used, popular tool for a variety of applications including gene therapy [16] [17] [18] [19] [20] is the piggyBac (PB) transposon originally isolated from the cabbage looper moth 21 .
Optimized vector components for enhanced Sleeping Beauty-mediated gene delivery
A number of improvements needed to be made to transform the original version of the SB transposon (pT) into an efficient tool for gene delivery in vertebrates. While originally the rate of transposition was low, steady improvements were made to optimize the vector architecture. Genetic engineering produced the variants pT/2/3/4, the most recent of which optimizes transposon binding [22] [23] [24] [25] . In addition, the so-called "sandwich" vector architecture (containing two full-lengh copies of SB flanking a gene-of-interest) was developed to aid transposition of large transgenes 12 .
Advanced genetic engineering also required variants of the transposase that were hyperactive compared to the original. Amino acid substitutions spanning almost the entire SB transposase polypeptide were screened to improve its catalytic activity. A second-generation SB transposase called SB11 26 proved to be about 3-fold more active than the first-generation SB transposase, and has been primarily employed in clinical trials based on chimeric antigen receptor (CAR)-engineered T cells that are currently underway 27 . Further improvements produced SB100X, the most hyperactive SB transposase version currently available, whose activity is ~100-fold that of the originally resurrected transposase 28 . SB100X transposase enables highly efficient germline transgenesis in relevant mammalian models, including mice, rats, rabbits, pigs, sheep and cattle [29] [30] [31] [32] [33] [34] . The system has also yielded robust gene transfer efficiencies into human hematopoietic stem cells (HSCs) 28, 35 , mesenchymal stem cells, muscle stem/progenitor cells (myoblasts), iPSCs 36 and T cells 37 , which are crucial targets for regenerative medicine and gene-and cell-based therapies aimed at complex genetic diseases.
Importantly, recent insights into structure-function relationships in the SB transposase based on modeling 38 and crystallography 39 will likely be informative for structure-based design of next-generation SB transposases for therapeutic gene delivery.
Typically, the delivery of the SB transposon system into cells supplies the two components of the vector system as conventional plasmids (Fig. 1B) . But the transposase expression plasmid typically used as the source of the transposase in cultured cell lines can be replaced by mRNA that is synthesized in in vitro transcription reactions ( Fig. 1D ), which was originally tested in a mammalian cell line in vitro and in the mouse liver in vivo, using the SB11 transposase 40, 41 . Although the nucleic acids carrying the SB vector components can only be partially be represented by RNA (the transposon is by definition DNA), the ex vivo application of mRNA for intracellular delivery of the transposase in therapeutically relevant cells avoids some of the hurdles typically encountered with DNA-based vectors. For example, nucleofecting primary human cells including HSCs and T cells with mRNA has a significantly lower toxicity than when plasmid DNA is used 42, 43 . Importantly, using mRNA source to transiently deliver the SB transposase increases biosafety, because mRNA does not run the risk of chromosomal integration. . Alongside a lower cytotoxicity, stable genome modification with MCs was more efficient than with conventional plasmid vectors in T cells 43 . Transfection of MC components is more efficient than that of plasmids owing to their smaller size, which enables them to cross cellular membranes more efficiently than plasmids 45, 46 . Another [51] [52] [53] , adenovirus 54, 55 , AAV 56 , herpes simplex virus 57, 58 and baculovirus 59, 60 . In these cases the SB transposon provides stable gene integration.
Safety aspects of Sleeping Beauty transposition
One of the most important risk factors associated with an integrating genetic element is genotoxicity: mutational damage that can shift cellular homeostasis toward some pathological path. This has happened in a number of recent clinical trials, in which retroviruses were used to transfer genes into HSCs, as described above: in some patients this has led to a clonal imbalance and tumorigenic transformation. Two fundamental properties of a transposon vector system potentially contribute to genotoxicity: i) if the transposase interacts with endogenous human DNA sequences or human proteins that are highly similar to the transposon vector sequences, or ii) if the vector is inserted into the genome at unsafe sites.
The SB system appears to be safe with respect to "off-target" cleavage of the transposase in human cells. Because the SB was reconstructed from fish genomes, the mammalian lineage does not contain transposons similar enough to it that they would be cleaved by the SB transposase. It is always possible that chance might produce genomic sequences similar to the SB TIRs, some of which might bind the SB transposase. However, SB transposition is such a highly controlled process 25 that it is extremely unlikely that these sequences would mobilize. Secondly, human cells do not express a protein similar enough to the SB transposase to re-mobilize a genomically integrated SB vector. In sharp contrast, the human transposase-derived protein PGBD5
can mobilize insect PB transposon vectors in human cells To estimate the genotoxic potential of different vector types and designs, it is important to characterize the properties, which influence their selection of target sites 63 .
We previously carried out a comparative study of the target site selection properties of the SB and PB transposons as well as MLV-derived gammaretroviral and HIV-derived lentiviral systems in primary human CD4 + T cells. Our bioinformatic analyses included mapping of integration sites generated by these four vector systems against the T cell genome with respect to their proximity to genes, transcriptional start sites (TSSs), CpG islands, DNaseI hypersensitive sites, chromatin marks, the transcriptional status of genes and criteria that qualify sequences as genomic safe harbors (GSHs) 64, 65 . Of the different systems, SB transposon targets displayed the least deviation from random in terms of genome-wide distribution. We found no apparent bias for either heterochromatin marks or euchromatin marks, and detected only a weak correlation with the transcriptional status of targeted genes 66 . Collectively, these analyses established that the SB transposon had a favorable integration profile compared to other vectors, suggesting that it might be safer for therapeutic gene delivery than the viral vectors that are currently being used to integrate sequences in clinical trials. Importantly, no adverse effects have been associated with SB in preclinical animal studies 6, 8, 67, 68 . Finally, SB's safety profile can probably be further improved through molecular strategies that enhance target-selected transgene integration 69 .
Therapeutic gene delivery with the Sleeping Beauty transposon system

In vivo application of the Sleeping Beauty system in pre-clinical models
In vivo applications use a gene vector system to shuttle a therapeutic nucleic acid delivered directly in the body; the delivery can be systemic, but more typically, it is targeted to a specific organ or cell type ( Fig. 2A) . The in vivo delivery of transposon vectors is challenging, because naked nucleic acids (DNA and mRNA) are unable to pass through the cell membrane through infection, unlike viruses. Thus, it is necessary to combine a transposon vector with a technology that can deliver a non-viral vector into cells. One of the most promising strategies is an in vivo gene transduction system based on a hybrid adenovirus/transposon vector 54 and the hyperactive SB100X transposase 55 ( Fig. 2A) . In a recent study, autologous HSCs were mobilized into peripheral blood, and directly targeted using such a hybrid adenovirus/transposon vector system in vivo, producing functional HSCs in a transgenic animal model 70, 71 . .
Ex vivo application of the Sleeping Beauty system in pre-clinical models
In ex vivo gene delivery, the therapeutic gene vector is introduced into a selected cell population that has been isolated from a donor, followed by the transplantation of the genetically engineered cells into a patient (Fig. 2B) . We distinguish between autologous or allogeneic cell products depending on whether the donor is the same patient or another person. As for in vivo applications, the efficiency of transposition depends on the efficiency, at which the nucleic acids that are introduced are taken up by cells. In TargetAMD is pursuing a strategy, by which genetically modified RPE or IPE cells that overexpress PEDF are transplanted into the subretinal space of the eye 50 ( Fig.   3) . Specifically, RPE or IPE cells isolated from the peripheral retina or obtained from an iris biopsy of a patient will be transfected with an SB transposon vector carrying a PEDF expression cassette. They will then be transplanted back into the same patient during one surgical session lasting about 60 minutes (Fig. 3) . A standard operating procedure has been established that i) consistently shows highly efficient transfer of the PEDF . This trial will make use of a CD19-CAR construct that has been selected from pre-clinical analyses for its optimal anti-tumor functions. It has already been validated in clinical trials of a CD19-CAR therapy based on lentiviral gene transfer 100, 108 . An additional step will be the 
Concluding Remarks and Future Perspectives
A number of studies have established that SB-mediated transposition provides long-term expression in vivo. Stable transgene expression from SB vectors has been observed in mice in the liver 11, [110] [111] [112] , lung 113, 114 , brain 115 and blood after hematopoietic reconstitution in vivo 28, 35 . of genes [117] [118] [119] [120] . Designer nucleases have the particular feature of introducing a doublestrand break (DSB) into the DNA, and are therefore highly efficient in mutagenizing a target site 121, 122 . However, adding a gene at the cut site requires the cellular process of homology-directed repair (HDR), whose efficiency is considerably lower than introducing the DSB in the first place 123 . In other words, using designer nucleases is far more efficient at knocking out a gene than inserting a gene into a specific site. In eukaryotic cells, DSBs can be repaired by at least two pathways: HDR and non-homologous end joining (NHEJ). HDR is strongly downregulated in most post-mitotic cells 124 ; thus, gene addition and gene repair require target cells that divide. In sharp contrast to designer nucleases, gene integration is a fundamental step of the life cycle of integrating viruses and transposable elements, and they have evolved machineries to achieve that. That means that vector systems based on such genetic elements exhibit a robust efficiency of gene insertion -a key requirement for medically relevant applications. An additional benefit is that some integrating vectors, particularly those based on transposons, can deliver their cargo into the genomes of non-dividing cells 11, 125 .
The advantages of using the SB system for gene therapy include i) the ease and 
